Skip to content

Blastomyces Dermatitidis Antigen (JWW)

by Meridian Diagnostics, Inc.

510(k) K792680

Active United States

510(k)

Valid until

No expiry

510(k) clearance is not time-limited

FDA recalls

None found

in data synced 6 Oct 2026

Documents

Trust

Unverified

Registry data, not yet checked by deviCERTS. Source FDA 510(k), synced 6 Oct 2026. What this means

Regulatory status

as of registry sync 6 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesFDA 510(k)SESE Substantially Equivalent · Traditional NumberK792680 Date17 Jan 1980ClearedStatusActive

Recalls

0 recalls · FDA

No FDA recalls found in the data synced 6 Oct 2026.

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — FDA 510(k) Active

Specification

510(k)

Full name
Blastomyces Dermatitidis, Antigen
510(k) Number
FDA Product Code
JWW
Device Class
Class II
Regulation
21 CFR Part 866.3060
Advisory Committee
Microbiology
FDA Decision
SESE Substantially Equivalent

Overview

AI-generated summary, 19 Sep 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

This device is an Antigen, Cf, B. Dermatitidis, classified under the Microbiology category. It is designed for diagnostic use in identifying Blastomyces dermatitidis antigens, aiding in the detection of infections caused by this fungal pathogen.

The antigen test is supplied as a Class 2 diagnostic device under 21 CFR 866.3060, cleared via the Traditional 510(k) pathway (K792680). It is intended for in vitro use with serum, plasma, or body fluids, though urine specimens require a separate assay. No regulatory status beyond the stated FDA clearance is implied.

Other devices from Meridian Diagnostics, Inc.

See all devices from Meridian Diagnostics, Inc. →

Questions

AI-generated answers, 19 Sep 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

  • What types of samples can this test detect *Blastomyces dermatitidis* antigens in, and are there any limitations?

    This test is designed for in vitro use with serum, plasma, or body fluids to detect *Blastomyces dermatitidis* antigens. However, urine specimens require a separate assay, so it is not suitable for direct urine testing without additional processing.

  • Is this device intended for single-use or can it be reused?

    The device is classified as a Class 2 diagnostic antigen test, which typically implies single-use for clinical diagnostic purposes. Reuse is not mentioned in the specifications, and reprocessing could compromise accuracy or sterility.

  • What regulatory pathway was used to clear this device, and what does that mean for its use?

    This device was cleared via the Traditional 510(k) pathway (K792680) under 21 CFR 866.3060, meaning it was determined to be substantially equivalent to a legally marketed predicate device. This clearance ensures it meets FDA standards for safety and effectiveness as an in vitro diagnostic for detecting *Blastomyces dermatitidis* antigens.

  • What medical specialty is this device primarily associated with, and why?

    This device falls under the Microbiology medical specialty category, as it is specifically designed for diagnostic use in identifying *Blastomyces dermatitidis* antigens. This classification aligns with its role in laboratory testing for fungal infections.